|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Georgia Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing GeorgiaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Galectin Therapeutics Inc.
| | | Phone: | (678) 620-3186 | Fax: | (770) 864-1327 | Year Established: | 2000 | Employees: | 4 | Ticker: | GALT | Exchange: | NASDAQ | Main Contact: | Harold H. Shlevin, Ph.D., CEO | | Other Contacts: | Rex Horton, Executive Director, RA & QA Jack W. Callicutt, CPA, CFO Eliezer Zomer, Ph.D., VP, Discovery R&D Adam E. Allgood, Pharm.D., R.Ph., Executive Director of Clinical Development
| | Company Description | Galectin Therapeutics (formerly Pro-Pharmaceuticals) is developing promising therapies for the treatment of fibrotic liver disease, skin diseases, and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. | |
|
|
|
|
|